Palisade Bio, Inc. (PALI) NASDAQ
1.83
+0.02(+1.10%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.83
+0.02(+1.10%)
Currency In USD
Address
5800 Armada Drive
Carlsbad, CA 92008
United States of America (the)
Phone
858 704 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
March 30, 2007
| Name | Title | Pay | Year Born |
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1.01M | 1958 |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 704,000 | 1977 |
| James Izanec | VP & Head of Clinical Development | 0 | N/A |
| Joerg Heyer | Head of Translational Science & Medicine | 0 | N/A |
| Daniel J. Larkins | Head of Global Regulatory Affairs | 0 | N/A |
| Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations | 0 | N/A |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | 0 | N/A |
| Sharon Skare | Vice President & Global Head of Clinical Operations | 0 | N/A |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | 0 | N/A |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.